These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1930 related articles for article (PubMed ID: 32145830)

  • 1. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
    N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
    Matteson EL; Kelly C; Distler JHW; Hoffmann-Vold AM; Seibold JR; Mittoo S; Dellaripa PF; Aringer M; Pope J; Distler O; James A; Schlenker-Herceg R; Stowasser S; Quaresma M; Flaherty KR;
    Arthritis Rheumatol; 2022 Jun; 74(6):1039-1047. PubMed ID: 35199968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
    Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
    Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
    Cottin V; Martinez FJ; Jenkins RG; Belperio JA; Kitamura H; Molina-Molina M; Tschoepe I; Coeck C; Lievens D; Costabel U
    Respir Res; 2022 Apr; 23(1):85. PubMed ID: 35392908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
    Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Sarr C; Freiwald M
    BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
    Maher TM; Brown KK; Kreuter M; Devaraj A; Walsh SLF; Lancaster LH; Belloli EA; Padilla M; Behr J; Goeldner RG; Tetzlaff K; Schlenker-Herceg R; Flaherty KR;
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34210788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
    Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB; Kolb M; Brown KK
    Respirology; 2023 May; 28(5):465-474. PubMed ID: 36642509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
    Ogura T; Suda T; Inase N; Nishioka Y; Azuma A; Okamoto M; Takizawa A; Ito T; Rohr KB; Inoue Y
    Respir Investig; 2022 Nov; 60(6):787-797. PubMed ID: 35927208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T; Stowasser S; Goeldner RG; Schlenker-Herceg R; Brown KK;
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials.
    Hoffmann-Vold AM; Volkmann ER; Allanore Y; Assassi S; de Vries-Bouwstra JK; Smith V; Tschoepe I; Loaiza L; Kanakapura M; Distler O
    Lancet Rheumatol; 2022 Oct; 4(10):e679-e687. PubMed ID: 38265966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.
    Mira-Avendano I; Kaye M
    Ther Adv Respir Dis; 2024; 18():17534666241266343. PubMed ID: 39113425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
    Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
    Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics.
    Kolb M; Flaherty KR; Silva RS; Prasse A; Vancheri C; Mueller H; Sroka-Saidi K; Wells AU;
    Adv Ther; 2023 Dec; 40(12):5536-5546. PubMed ID: 37751022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 97.